Intuitive Surgical (DE:IUI1)
XETRA:IUI1
IUI1 Stock Chart & Stats
€388.85
€9.00(1.73%)
At close: 4:00 PM EST
€388.85
€9.00(1.73%)
Day’s Range― - ―
52-Week Range€364.60 - €516.10
Previous CloseN/A
Volume235.00
Average Volume (3M)232.00
Market Cap
€137.68B
Enterprise Value€157.79B
Total Cash (Recent Filing)€5.93B
Total Debt (Recent Filing)€302.80M
Price to Earnings (P/E)70.8
Beta0.59
Next Earnings
Apr 21, 2026EPS Estimate
1.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.17
Shares Outstanding355,130,250
10 Day Avg. Volume240
30 Day Avg. Volume232
Financial Highlights & Ratios
PEG Ratio3.17
Price to Book (P/B)11.34
Price to Sales (P/S)20.08
P/FCF Ratio81.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€544.98Price Target Upside40.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
EPS Forecast (FY)8.56
Revenue Forecast (FY)€9.85B
Bulls Say, Bears Say
Bulls Say
Acquisition And Technology IntegrationAcquisition of a company developing integrated robotics and AI for tissue assessment strengthens the surgical robotics portfolio and creates potential for intraoperative decision support across multiple disease areas.
Imaging InnovationAdvances in dye-free hyperspectral oxygenation imaging promise quantitative tissue maps without contrast agents, which could improve surgical decision making and reduce workflow complexity in operations.
Regulatory ApprovalsFDA clearance expanding cardiac procedures on the latest surgical system broadens the range of cases addressable by the platform, increasing the long-term market opportunity for higher‑complexity surgeries.
Bears Say
Adoption Pace For Complex ProceduresAnalyst notes that the inherent complexity of cardiac procedures will likely lead to gradual robotic adoption, limiting near-term market penetration and delaying revenue ramp from new cardiac indications.
Product Safety And Regulatory RiskReports of serious adverse events and an FDA alert to stop using affected reloads raise safety and reputational concerns that could prompt further regulatory actions and disrupt customer usage patterns.
Valuation RiskA rich valuation premium relative to large-cap medical device peers increases downside vulnerability if growth or adoption trends slow or competitive pressures intensify.
Intuitive Surgical News
IUI1 FAQ
What was Intuitive Surgical’s price range in the past 12 months?
Intuitive Surgical lowest stock price was €364.60 and its highest was €516.10 in the past 12 months.
What is Intuitive Surgical’s market cap?
Intuitive Surgical’s market cap is €137.68B.
When is Intuitive Surgical’s upcoming earnings report date?
Intuitive Surgical’s upcoming earnings report date is Apr 21, 2026 which is in 13 days.
How were Intuitive Surgical’s earnings last quarter?
Intuitive Surgical released its earnings results on Jan 22, 2026. The company reported €2.165 earnings per share for the quarter, beating the consensus estimate of €1.94 by €0.225.
Is Intuitive Surgical overvalued?
According to Wall Street analysts Intuitive Surgical’s price is currently Undervalued.
Does Intuitive Surgical pay dividends?
Intuitive Surgical does not currently pay dividends.
What is Intuitive Surgical’s EPS estimate?
Intuitive Surgical’s EPS estimate is 1.82.
How many shares outstanding does Intuitive Surgical have?
Intuitive Surgical has 355,130,250 shares outstanding.
What happened to Intuitive Surgical’s price movement after its last earnings report?
Intuitive Surgical reported an EPS of €2.165 in its last earnings report, beating expectations of €1.94. Following the earnings report the stock price went down -1.502%.
Which hedge fund is a major shareholder of Intuitive Surgical?
Currently, no hedge funds are holding shares in DE:IUI1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Intuitive Surgical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€544.98 (40.15% Upside)
€544.98 (40.15% Upside)
Blogger Sentiment
Bullish
DE:IUI1 Sentiment 85%
Sector Average 69%
Sector Average 69%
News Sentiment
Bullish
Bullish news 60%
Bearish news 40%
Bearish news 40%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.22%
12-Months-Change
Fundamentals
Return on Equity
16.39%
Trailing 12-Months
Asset Growth
9.52%
Trailing 12-Months
Company Description
Intuitive Surgical
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
IUI1 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call described strong top-line and procedure growth, meaningful increases in cash flow and profitability, rapid adoption of new platforms (da Vinci 5, SP, Ion), and continued product and clinical progress. Offsetting these positives are margin pressures from tariffs and product mix, elevated operating expenses (including a large foundation donation and hiring), competitive pricing/tender dynamics in China, placement softness in Japan, and lower Ion placements in Q4. On balance the company reported multiple high-growth metrics and solid cash generation while outlining manageable but notable near-term headwinds.View all DE:IUI1 earnings summariesIUI1 Revenue Breakdown
67.72% U.S.
32.28% Outside of U.S
IUI1 Stock 12 Month Forecast
Average Price Target
€544.98
▲(40.15% Upside)
Technical Analysis
Baxter International
―
Becton Dickinson
―
Hologic
―
Resmed
―
West Pharmaceutical Services
―
Options Prices
Currently, No data available
---